SEMAX 10MG

Semax is a synthetic heptapeptide analog of ACTH(4–10) developed in Russia and studied primarily for cognitive enhancement and neuroprotection. While intranasal administration is most common in clinical literature, subcutaneous injection offers a convenient once‑daily alternative for research purposes.

Semax is a synthetic analog of the ACTH(4–10) fragment with a C‑terminal Pro‑Gly‑Pro tripeptide extension that enhances metabolic stability. Clinical and preclinical literature suggest it modulates brain‑derived neurotrophic factor (BDNF) expression, enhances cholinergic and dopaminergic neurotransmission, and exhibits neuroprotective properties in models of cerebrovascular and cognitive impairment. Human studies in Russia have employed Semax for cognitive support in conditions ranging from mild cognitive impairment to acute stroke recovery, typically using intranasal administration. Subcutaneous delivery offers an alternative route with potentially more sustained systemic absorption.

Goal : Support cognitive function, attention, and neuroprotective pathways studied in clinical literature.

Schedule : Daily subcutaneous injections for 8 weeks (extend to 12-16 weeks with cycling if desired).

Dose Range : 300-800mcg daily with gradual titration; aligns with typical human nootropic dosing ranges

Reconstitute : Add. 3mL Bacteriostatic Water (6 units = 200mcg)

Dosing Protocol :
Suggested daily titration approach.

• Start : 300mcg daily, increase by ~100-200mcg every 1-2 weeks as tolerated.
• Target : 600-800 mcg daily by Weeks 5-8, adjust based on individual response.
• Frequency : Once per day (subcutaneous).
• Cycle Length : 8 weeks continuous, optional extension to 12-16 weeks with off‑periods (e.g., 6 weeks on, 2 weeks off).
• Timing : Any consistent time; rotate injection sites systematically.